Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Generic Office Director Uhl Returns From Medical Leave

This article was originally published in The Pink Sheet Daily

Executive Summary

Kathleen Uhl's five-month leave for cancer treatment ends as user fee negotiations move towards formal start.

You may also be interested in...



Generics Office At US FDA Could Get New Director Before Uhl Departs

Kathleen Uhl gave seven months' notice of her retirement, which may allow new director to be hired and on-boarded before she departs.

US FDA Generic Drug Office Director Uhl Announces Retirement

Uhl, who shepherded OGD into the user fee era, will retire in February.

US FDA Generic Drug Office Director Uhl Announces Retirement

Uhl, who shepherded OGD into the user fee era, will retire in February.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel